» Articles » PMID: 11509079

T1 Lesion Load and Cerebral Atrophy As a Marker for Clinical Progression in Patients with Multiple Sclerosis. A Prospective 18 Months Follow-up Study

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2001 Aug 18
PMID 11509079
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the relationship between local tissue destruction, diffuse cerebral atrophy and clinical progression in patients with established multiple sclerosis (MS). Twenty-nine patients with MS (13 patients with relapsing--remitting and 16 with secondary progressive disease) were included in a prospective serial study. Cerebral volumes, T1 hypointense lesion volumes, T2 hyperintense lesion volumes at baseline and at 18 months follow-up, and the volume of monthly enhancing lesions from month 0 to month 9 were assessed on magnetic resonance imaging (MRI) brain scans using highly reproducible semi-automated quantitative techniques. The main outcome measures were the MRI parameters and disability on Kurtzkes' Expanded Disability Status Scale. There was a significant correlation between the change (increase) in T1 lesion volume and progressive cerebral atrophy, whereas no correlation between the T2 lesion volume and atrophy was seen over the same follow-up period. The change in T1 lesion volume correlated more strongly than did T2 lesion volume change with the change in disability. We conclude that hypointense abnormalities detected in T1-weighted brain scans and cerebral atrophy may be directly linked. Although one should bear in mind some potential for reversibility due to inflammatory, oedematous lesions, these MR measures are a useful marker of progressive tissue damage and clinical progression in established MS.

Citing Articles

Analysis and visualization of the effect of multiple sclerosis on biological brain age.

Romme C, Stanley E, Mouches P, Wilms M, Pike G, Metz L Front Neurol. 2024; 15:1423485.

PMID: 39450049 PMC: 11499186. DOI: 10.3389/fneur.2024.1423485.


Pediatric Onset Multiple Sclerosis and Obesity: Defining the Silhouette of Disease Features in Overweight Patients.

Papetti L, Panella E, Monte G, Ferilli M, Tarantino S, Proietti Checchi M Nutrients. 2023; 15(23).

PMID: 38068737 PMC: 10707944. DOI: 10.3390/nu15234880.


Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients.

Kelly E, Varosanec M, Kosa P, Prchkovska V, Moreno-Dominguez D, Bielekova B Front Radiol. 2023; 2:1026442.

PMID: 37492667 PMC: 10365117. DOI: 10.3389/fradi.2022.1026442.


The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.

Gentile G, Mattiesing R, Brouwer I, van Schijndel R, Uitdehaag B, Twisk J Neuroimage Clin. 2023; 38:103397.

PMID: 37086648 PMC: 10300577. DOI: 10.1016/j.nicl.2023.103397.


Predictors of long-term disability in multiple sclerosis patients using routine magnetic resonance imaging data: A 15-year retrospective study.

Altokhis A, Alotaibi A, Morgan P, Tanasescu R, Evangelou N Neuroradiol J. 2023; 36(5):524-532.

PMID: 36745094 PMC: 10569198. DOI: 10.1177/19714009221150853.